Back to Search
Start Over
Complete response with anti-PD-L1 antibody following progression on anti-PD-1 antibody in advanced non-small cell lung cancer
- Source :
- BMJ Case Rep
- Publication Year :
- 2020
- Publisher :
- BMJ, 2020.
-
Abstract
- Immune-checkpoint inhibitors (ICI), specifically inhibitors of programmed death ligand-1 (PD-L1) and receptor (PD-1) are the new standard of care for the treatment of patients with advanced non-small cell lung cancer (NSCLC) in front line setting as monotherapy or along with chemotherapy. Many of these agents are also approved for use in subsequent lines of treatment on progression on platinum doublet chemotherapy. Nivolumab, pembrolizumab and atezolizumab are currently approved ICI for advanced NSCLC. To date, no study has reported efficacy and safety of alternate PD-1/PD-L1 inhibitors in patients with NSCLC who have progressed on one ICI. Here, we report a case of a patient with advanced NSCLC who had a complete response to atezolizumab, following progression of disease on platinum doublet chemotherapy and then, nivolumab monotherapy.
- Subjects :
- Male
Oncology
medicine.medical_specialty
Lung Neoplasms
medicine.medical_treatment
Antineoplastic Agents
Pembrolizumab
Disease
Antibodies, Monoclonal, Humanized
03 medical and health sciences
0302 clinical medicine
Atezolizumab
Carcinoma, Non-Small-Cell Lung
Internal medicine
medicine
Humans
Lung cancer
Novel Treatment (New Drug/Intervention
Established Drug/Procedure in New Situation)
Aged
Platinum
Chemotherapy
biology
business.industry
General Medicine
medicine.disease
respiratory tract diseases
Nivolumab
030220 oncology & carcinogenesis
Disease Progression
biology.protein
Non small cell
Antibody
business
030215 immunology
Subjects
Details
- ISSN :
- 1757790X
- Volume :
- 13
- Database :
- OpenAIRE
- Journal :
- BMJ Case Reports
- Accession number :
- edsair.doi.dedup.....e401c166261b8f240339a059cdc16871